Merck Announces Fourth-Quarter and Full-Year 2020 Financial …
网页2021年2月4日 — KENILWORTH, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2020. “Despite extraordinary challenges brought on by the COVID-19 pandemic, Merck achieved solid growth and made meaningful progress in …
Merck Annual Report 2020 - Home
网页2021年3月4日 — We have successfully weathered the pandemic so far. That’s because the strengths of our business model with three innovation-driven business sectors have become particularly evident during the Covid-19 crisis. Thanks to our clear focus on science and technology, we are very well positioned even during economically challenging times.
Download Center - Merck Annual Report 2020
网页2021年3月4日 — Risks due to the divestment, acquisition, and integration of companies and businesses. Management assessment. Report on Expected Developments. Report in …
Financial Results 2020 - Merck
网页Merck had a successful fiscal 2020, a year that was marked by the Covid-19 pandemic. The company met all the financial targets it had set for itself. Overview and Outlook. Fiscal 2020. Sales increase by 8.6% to € 17.5 billion; EBITDA pre jumps 18.6% to € 5.2 billion; EBITDA pre margin rises to 29.7%; earnings per share pre grow 20.5% to € 6.70.
Financial information - Merck.com
网页Contact investor relations. (732) 594-1468. [email protected]. Explore our quarterly reports, annual reports & proxy. Merck is the world's premier research-intensive biopharmaceutical company.
Merck Announces First-Quarter 2020 Financial Results
网页2020年4月28日 — First-quarter pharmaceutical sales increased 10% to $10.7 billion, excluding the unfavorable effect from foreign exchange, sales grew 12%. The increase was driven primarily by growth in oncology and vaccines, partially offset by the ongoing impacts of the loss of market exclusivity for several products.
- [PDF]
Merck & Co., Inc.
网页In February 2020, Merck announced its intention to spin-off (the Spin-Off) products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders.
The Merck Index Online - chemicals, drugs and biologicals
网页For over 130 years The Merck Index has been regarded as the most authoritative and reliable source of key physical, pharmacological and historical information on chemicals, drugs and biologicals. Since 2013, it has been updated by the Royal Society of Chemistry.
Merck Revenue 2010-2024 | MRK - Macrotrends
网页Merck annual revenue for 2022 was $59.283B, a 21.72% increase from 2021. Merck annual revenue for 2021 was $48.704B, a 17.31% increase from 2020. Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD …
Merck Annual Report 2020
网页Apart from our three business sectors, our financial reporting presents five regions: Europe, North America, Asia-Pacific, Latin America, and the Middle East & Africa. As of December 31, 2020, we had 58,127 employees worldwide 1. This compares with 57,071 employees as of December 31, 2019.
- 某些结果已被删除
跳至内容